Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2020-12-23 Director's Dealing
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Change of Directors' Interest Notices 12 pages 644.5KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in directors' relevant interests in securities, including the number of shares and performance rights acquired or disposed, dates of changes, and nature of interests. The document is a formal notification to the ASX about directors' personal share transactions and interests. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document is not an annual report, earnings release, or any other financial report type, nor is it a regulatory announcement or proxy material. Therefore, the correct classification is DIRS.
2020-12-23 English
Appendix 3G 14 pages 254.3KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the ASX (Australian Securities Exchange) regarding the notification of issue, conversion, or payment up of equity securities. It details the issuance of various securities including warrants, performance rights, and options, specifying quantities, exercise prices, expiration dates, and recipients including key management personnel. The document is a regulatory announcement about new securities issued by the company Genetic Technologies Limited. It is not a financial report, earnings release, or management discussion, but rather a formal notification of capital changes related to share issuance and securities. This fits the definition of a Share Issue/Capital Change announcement (SHA). The document length is substantial and contains detailed information about the securities issued, consistent with a capital change filing rather than a brief announcement or a report publication notice.
2020-12-20 English
Chairman's AGM Address 2 pages 165.5KB
AGM Information Classification · 95% confidence The document is titled 'CHAIRMAN’S ADDRESS TO 2020 AGM' and is dated 10 December 2020. It is a speech or address given by the Chairman ahead of the Annual General Meeting (AGM) of Genetic Technologies Limited. The content focuses on company progress, challenges, and future outlook, typical of a chairman's address at an AGM. There is no detailed financial data or comprehensive report content, but rather a presentation-style communication to shareholders at the AGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length is about 4911 characters, which is consistent with a detailed AGM address but not a full annual report or financial filing. Therefore, the appropriate classification is AGM Information (AGM-R).
2020-12-09 English
AGM Presentation 13 pages 3.6MB
AGM Information Classification · 95% confidence The document is titled 'AGM Presentation December 10th 2020' and contains detailed presentation slides about the company's business, products, pipelines, sales, distribution, corporate information, progress over the year, and plans for the next 12 months. It is clearly a presentation prepared for the Annual General Meeting (AGM) of Genetic Technologies Limited. The content is structured as a slide deck with forward-looking statements, product descriptions, market strategy, and corporate updates, which are typical for AGM presentations. There is no indication that this is a full annual report, earnings release, or other regulatory filing. The length (12,707 characters) and format support it being a presentation rather than a brief announcement or certification. Therefore, the appropriate classification is AGM Information (AGM-R).
2020-12-09 English
Results of Meeting 3 pages 120.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an ASX Market Announcement titled 'Results of Annual General Meeting' for Genetic Technologies Limited, dated 10 December 2020. It provides detailed voting results for resolutions passed at the AGM, including adoption of the remuneration report, re-election of directors, approval of share issues, and appointment of auditor. The document references ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, which relate to disclosure of voting results. The content is focused on the official results of shareholder votes at the AGM, not the AGM materials themselves or the full annual report. The document length is 5567 characters, which is sufficient to include detailed voting results rather than just an announcement of report publication. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-12-09 English
Updated Announcement 4 pages 327.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Ltd dated 2 December 2020. It updates a previous announcement regarding a distribution agreement for PREDICTIX products. The content focuses on the terms of the partnership, minimum costs, distribution rights, and product details. There are no financial statements, quarterly or annual results, or detailed financial analysis present. The document is a corporate announcement about a business partnership and distribution rights, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information about the agreement itself rather than just announcing a report's release. Therefore, the document fits best into the category of Capital/Financing Update (CAP), as it relates to a business agreement impacting the company's product distribution and potential revenue streams.
2020-12-01 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.